Drugs Made In America Acquisition Corp. (DMAAR) Non-Current Assets (2024 - 2026)

Drugs Made In America Acquisition (DMAAR) has reported Non-Current Assets for 3 consecutive years, with $146.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets fell 37.56% year-over-year to $146.8 million; the trailing twelve-month figure through Jun 2026 stood at $146.8 million (changed N/A YoY), and the FY2025 full-year result was $239.9 million, up 43852.39% from the prior year.
• Non-Current Assets retreated to $146.8 million in Q2 2026 per DMAAR's latest filing, from $239.9 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $239.9 million in Q4 2025 and bottomed at $545833.0 in Q4 2024.
• Historically, Non-Current Assets has averaged $182.1 million across 3 years, with a median of $233.9 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Non-Current Assets jumped 43852.39% in 2025, then slumped 37.56% in 2026.
• Over 3 years, Non-Current Assets stood at $545833.0 in 2024, then surged by 43852.39% to $239.9 million in 2025, then sank by 38.8% to $146.8 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $146.8 million, $239.9 million, and $237.6 million for Q2 2026, Q4 2025, and Q3 2025 respectively.